Avestha Gengraine Technologies Pvt Ltd, India's leading biotechnology company, has entered into a joint venture with the Denmark-based Centre for Clinical & Basic Research (CCBR) and its subsidiary Nordic Biosciences. The companies will work together on a wide array of aspects covering the diagnosis, treatment and prevention of osteoporosis and osteoarthritis.

Avesthagen will be intimately involved with CCBR in putting together a comprehensive platform to develop novel technologies that integrate the diagnosis and treatment of osteoporosis. The two companies will also work together to develop the market in India and worldwide for a biomarker-based diagnostic kit that significantly improves on existing technology, release from Avastahgen said. Avesthagen and CCBR's plan to jointly market these products globally.

Addressing the conference, Dr. Villoo M Patell, Founder & CEO, Avestha Gengraine Technologies Pvt Ltd said, "We look forward to our partnership with CCBR. We are confident that this combination of two companies will help improve the current paradigm of osteoporosis care and prevention."

Speaking at the occasion to announce the tie-up Dr. Claus Christiansen, Founder & CEO, Centre for Clinical & Basic Research said, "We are happy to tie-up with Avesthagen, this partnership will be crucial to jumpstarting the Indo-Danish collaborations in the biotech industry. Our joint venture will address the needs of Osteoporotic patients worldwide."

Centre for Clinical & Basic Research (CCBR) is an international company performing clinical trials for the pharmaceutical industry. CCBR is furthermore a research centre that performs protocol writing and scientific publication. The main work are of CCBR are osteoporosis, osteoarthritis, hypertension, and type II diabetes.

Nordic Bioscience is a Danish, biotech company involved in the development of therapeutic compounds and diagnostic products for patients suffering from diseases affecting bone and cartilage, such as osteoporosis, osteoarthritis and bone metastasis.